AD_____

Award Number: W81XWH-09-1-0069

TITLE: Defining Genomic Changes in Triple Negative Breast Cancer in Women of African Descent

PRINCIPAL INVESTIGATOR: Lisa Baumbach, PhD

CONTRACTING ORGANIZATION: University of Miami
                          Miami, Florida 33136

REPORT DATE: June 2010

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

☒ Approved for public release; distribution unlimited

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE *(DD-MM-YYYY)*	2. REPORT TYPE	3. DATES COVERED *(From - To)*
23-Lwp-2010	Annual	03'LWP''422; ''/'53'O C['''4232

4. TITLE AND SUBTITLE

Defining Genomic Changes in Triple Negative Breast Cancer in

Women of African Descent

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-09-1-0069

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)

Lisa Baumbach, PhD
Go ckn'''rdcwo dceB o gf 0 kco k0gf w

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Miami
O kco kHN''55358

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research
And Materiel Command   Fort Detrick, MD 21702

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

Breast cancer (BC) is the second leading cause of cancer death among African-American (AA) women, with a 20% greater death rate than in Caucasians (Cauc). However, the basis for such disparity remains an enigma. Recent observations from our laboratory suggest the involvement of novel genes contributing to AA BC risk. Tumor and normal breast tissue samples from Cauc and AA patients were obtained from the UM /Sylvester Breast Tissue Bank (UM/S BTB). Our main goal was to identify which genes were turned "on" (expressed) and which genes were turned "off" (using gene "chip" technology) between tumor and normal samples that were both common and unique among ethnic groups. Based on analysis of 22,000 genes, some common changes in breast cancer were identified, as well as *ethnic specific* gene expression patterns that may provide important new insights into ethnic differences in clinical outcomes. In this study, we proposed to extend these preliminary findings to a much larger native African tumor bank [available via collaboration between Drs. Peter A. Bird (a missionary surgeon in Kijabe, Kenya) and Mark Pegram (UM Sylvester).] Additionally, we propose to analyze structural chromosomal alterations associated with gene expression differences utilizing advanced genomic techniques (in collaboration with Alan Ashworth, England).

The underlying hypothesis of the overall project is that discrete genomic alterations and gene expression changes will be identified and shared between triple negative tumor specimens within an ethnic group, i.e., North Americans/African descent and Kenya. The method in which this is being investigated includes three approaches: gene expression studies in breast cancer samples of African-American ancestry vs. native African samples, investigation of possible chromosomal or copy number alterations in the same samples and an analysis of a panel of ancestry-informative DNA markers. The study cohort consists of 50 African-American breast cancer samples and 50 Kijabe (Kenyan) Native African breast cancer samples.

This work will contribute to development of rationale designs of preventive, predictive and therapeutic measures for BC in different ethnicities, and thus, a significant reduction in current ethnic-specific disparities in BC incidence, morbidity and mortality.

15. SUBJECT TERMS
Triple negative breast cancer, Ethnic disparities, Breast cancer among African Americans and Africans, Gene expression profiling, Array CGH

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	UU	13	19b. TELEPHONE NUMBER *(include area code)*

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std Z39 18

Table of Contents

3) INTRODUCTION

Staggering statistics arise from analysis of cancer disparities. Breast Cancer (BC) is the second leading cause of cancer death among African-American (AA) women (1). Mortality is 20% greater than that in Caucasian (Cauc) women, and is partially attributed to more aggressive disease and poorer prognosis. In addition, AA women < 50 years have the highest rate of new BC cases in the US (1,2). General consensus exists that AA women of all ages are more likely to have poorly differentiated BC, which is likely to occur at an earlier age, be ER and PR negative, and to have a higher proliferative fraction - all factors associated with more aggressive tumorgenicity (2). Therefore, the prognosis in AA patients is worse, even adjusted for stage of presentation. Ethnic-specific differences in response to adjuvant therapy have also been reported (3,4). Taken together, the cumulative data suggests that intrinsic, ethnic-specific, and biological/genetic differences contribute to disparities in BC morbidity and mortality. Very few studies have directly compared multi-ethnic differences in breast cancer incidence, staging, tumor characteristics, and mortality in the United States.

A number of articles have been written concerning the incidence and types of breast cancer among native Africans in Nigeria and Kenya (5-10). All of these studies are in agreement that Nigerian women develop BC at an earlier age and suffer high mortality. . An important recent study by Bird et al (11) focused on a cohort of BC patients from the Kijabe Hospital in Kenya and reported a very low frequency of hormone receptor expression: 24% ER-positive and 34% ER-or PR-positive tumors. Compared to BC in Western or Cauc populations, the Kijabe patients have a high proportion of poorly differentiated, advanced cancers and irrespective of disease stage, were much less likely to be hormone sensitive (ER and PR negative). Overall, the possibility of inherently more aggressive tumor biology, coupled with low hormone receptor sensitivity and lack of HER2, may represent manifestations of modified biology in African populations. Further research is urgently needed to fully characterize the tumors in the Kijabe clinical cohort, and to determine whether BC subtypes with a poor prognosis are overrepresented in the African race. Comparative molecular studies of BC in indigenous African populations, African Americans, and Caucasian Americans are needed to allow genetic and molecular detailing of these tumors that appear to have modified biology relative to breast cancers in other populations.

We have developed a collaboration with *Almac Diagnostics* (*www.almacgroup.com*). In a early pilot study, samples from three AA and three Cauc BC patients (matched for age; ER+/PR+/Her 2-) demonstrated feasibility of the *Almac* platform in formalin-fixed, paraffin-embedded (FFPE) samples obtained from UM Pathology laboratories. Next, a broader multi-ethnic project focusing on triple negative breast cancer cases in AA, His and Cau patients was initiated. An investigation of 28 cases (10 AA cases, 8 Cauc cases and 10 His cases). Analysis of the detected transcripts for each patient demonstrated low variability between samples and a high number of detected transcripts. Across all 56 samples (28 tumor and 28 matched normal), greater than 22,000 transcripts were detected significantly above background (*data not shown*). Further statistical analyses (including ANOVA and T-tests) resulted in the identification of 2,622 statistically significant, differentially expressed genes. The 2,622 genes were used as input sequences for the expression pattern identification across the six sample groups (tumor and normal in 3 ethnic groups). In the tumor samples, six ethnic-specific expression patterns were identified in the resultant heatmap. The subset of differentially expressed genes was analyzed using real-time PCR to validate gene expression differences. To summarize, even in a small pilot study, we have identified both common and ethnic-specific transcriptional changes between AA and Cauc breast cancer samples. If confirmed in larger data sets, these observations may well provide important new insights into molecular mechanisms of ethnic subtype differences in clinical outcomes.

The current project is a study of the potential differences or similarities between a cohort of African-American triple negative cases with a cohort of triple negative cases from Kijabe (Kenya) obtained through collaboration with Dr .Peter Bird (Nairobi, Kenya). It applies the gene expression array technology described above in addition to investigation of possible chromosomal or copy number alterations in the same samples

(through collaboration with Dr. Alan Ashworh, England) and an analysis of a panel of ancestry-informative DNA markers (through collaboration with Dr. Rick Kittles, Chicago).

4) BODY

Task 1: Obtain UM IRB and USAMRMC HRPO Approvals. Status: Completed

Approval by the UM Institutional Review Board for Human Subjects research was obtained on May 6, 2009. It is UM protocol number 20081188. The title of the protocol is the same as the grant "Defining Genomic Changes in Triple Negative Breast Cancer in Women of African Descent" It was approved as Exempt status.

Task 2: Transport of Kijabe samples to the University of Miami. Status: Completed

We received the Kijabe native African breast cancer samples from Dr. Peter Bird, the last were received in December 2009. To date we have received 64 samples from Africa. Dr. Bird and Dr. Pegram will be meeting during the ASCO meeting in Chicago this June to discuss the progress on the project.

Task 3. Determination of HER2 status in the Kijabe clinical cohort using fluorescence in situ hybridization. Status: Underway

In the original proposal we indicated that we would need to determine the HER2 status of the Kijabe samples as it is not commonly performed during the cancer treatment for these individuals. ER and PR receptor status assays are available for most of the samples. We evaluated an initial subset of 10 Kijabe samples for ER, PR and Her2 status in the UM Pathology laboratory. Comparison with the available ER and PR status from Africa showed a couple of discrepancies in ER or PR status. These samples were repeated and the discrepancies remained, therefore, it was decided that we should redo ER and PR status testing for all of the Kijabe samples, as well as testing Her2 status. With the addition of this work we have not completely finished receptor status testing for all of the Kijabe samples, but anticipate completion in a few weeks. All of the UM African-American samples have ER/PR and Her2 status already available.

Task 4: Extraction and preparation of DNA and RNA from FFPE tumor samples from North American African, African African, and Caucasian cohorts. Status: Underway

Separate extraction procedures are done for the extraction of DNA or RNA from the FFPE tumor and normal tissue subsamples for each patient sample. The quality or purity of the extracted samples is evaluated looking at the overall concentration, the A260/280 ratio and the presence/quality of distinct 18S and 28S peaks using a bioanalyzer for RNA. The UM Pathology samples have shown a consistent high yield of good quality RNA/DNA. Extractions of the Kijabe African samples is not yet complete, but will be completed when the final ER/PR/Her2 status information is available, which will allow for preferential treatment of the triple negative samples.

Task 5: Aim I, Analyze and compare genome-wide transcript expression in BC samples of AA ancestry vs. native African (Kijabe) samples. Status: Underway

To date about half of the total African-American samples have been hybridized to the Almac Breast Cancer DSA chip and a selected few Kijabe samples have been hybridized. Numerous Caucasian samples have also been analyzed (see Pegram PI report for sample tables). The quality of resulting data was excellent. Detailed steps in quality control and data analyses are further discussed below.

A) Distribution Analysis: The distribution of the sample data (histogram of normalised intensity values) is assessed to determine what statistical tests, metrics; etc should be applied. Data showed a normal (Gaussian) distribution, therefore a Pearson correlation, which is based on the normal distribution, was chosen for clustering.


Figure 1. Data Distribution for initial African-American samples on DSA arrays. Data distribution was examined using all transcripts on the breast cancer DSA chip. Each sample group was from combining all samples from an ethnic group with same condition (tumor or normal). The data distribution is close to normal, indicating it is suitable for the data analysis.

B) K-Mean Clustering: Groups were created which show the relationships among the expression levels of conditions (tumor vs. normal) or samples. This allowed identification any spurious samples. K-Mean was used because of prior knowledge of sample condition either from tumor or normal tissue. Samples falling into a group that does not match their biological condition would suggest potential abnormality or contamination of tumor and normal tissue.

Inclusion of one contaminated "normal' sample from an African-American patient in the two-dimentional K-mean clustering analysis showed that this "normal" sample exihibited tumor-like gene expression profile and fell into the tumor cluster (see Figure 2 below).

6

Figure 2. Identification of contaminated cells in an FFPE sample. On the far right, one dissected FFPE slice of normal cells exhibits similar gene expression pattern to tumor cells.

C) Principal Components Analysis: This data analysis technique is a decomposition technique that produces a set of expression patterns known as principal components. Linear combinations of these patterns can be assembled to represent the behavior of all of the genes in a given data set. PCA is not a clustering technique; however the aim of PCA is similar to that of clustering. It is a tool to characterize the most abundant themes or building blocks that reoccur in many genes in the experiment. See the Pegram PI report for illustration of the PCA results.

D) Native African samples yield good quality RNA and Data:
Illustrated below is a preliminary analysis of the first Kijabe samples. These samples have been through the data quality and analysis steps described above. The heatmap displayed here is a comparison of triple negative Kijabe, Native African samples to adjacent normal tissue samples from African-Americans. The Kijabe samples clearly cluster together separate from the African-American samples. Some differences can be seen within the African-American samples and within the Kijabe samples. These differences may be due to different nodal status but are being evaluated in the correlation with clinical parameters (Task 10).

7

Figure 3 .Cluster diagram from analysis of the initial triple negative Native African samples. This comparison shows that high quality RNA can be extracted from the Kijabe samples**.**

Task 6: Aim II, Investigate possible chromosomal alterations associated with gene expression differences using array cGH. Status: Underway

DNA extracted from each tumor and normal sample are being hybridized to high density cGH arrays in the laboratory of Dr. Alan Ashworth at the Breakthrough Cancer Center in England. Data is assessed for quality and analyzed for copy number variation and possible chromosomal aberrations. The array being used is an aCGH 32K tiling path microarray, which has a complete coverage of the whole genome with a resolution of 50kb.

A) DNA labelling and array hybridization
Reference (pool normal DNA extracted from blood lymphocytes from 24 individuals) and tumor DNA samples (300 ng aliquots) are labeled with Cy3- or Cy5-conjugated dCTP respectively (Amersham Biosciences, Buckinghamshire, UK) using random primer BioPrime DNA labeling. Labeled reference and tumor DNA are co-ethanol precipitated with 100 µg human Cot-1 DNA (Invitrogen Life Technologies) and re-suspended in 45 µl hybridization buffer; denatured and incubated at 37 °C to allow blocking of repetitive sequences by human Cot-1 DNA. Denatured DNA samples are then hybridized to the microarray at 37 °C for 18 h. The arrays are then washed and dried by centrifugation. aCGH slides are scanned using an Axon 4000B scanner (Axon Instruments, Burlingame, CA, USA) and images will be processed using Genepix Pro 4.0 image analysis software (Axon Instruments). See Figure 4 below for an example of hybridization of a Kijabe Native African case.

Figure 4. Scanned image of Kijabe Native African Case.
The image is the result of merging the reference sample data with
that from the tumor sample, prior to final data analysis.

B) Data analysis

Cases with >10% of clones missing and clones for which data are not available in ≥10% of cases will be
excluded. Log2 ratios will be normalized for spatial and intensity dependent biases using a two-dimensional
loess regression followed by a BAC-dependent bias correction. The final dataset of BAC clones with
unambiguous mapping information according to the build hg19 of the human genome
(http://www.ensembl.org) are used for further analysis. Analysis of samples is currently underway in Dr.
Ashworth's lab. Our lab in Miami is in regular contact with Dr. Ashworth's lab and Dr. Ashworth has visited
Miami, while in the US. Drs. Baumbach and Pegram also meet with Dr. Ashworth at cancer meetings such
as the AACR. Co-analysis of expression array and array cGH data to correlate changes in gene expression
with gene copy number will be completed in Year 2 of the project.

**Task 7: Aim III, Analyze ancestry of each sample using a panel of ancestry-informative DNA markers
(AIMs). Status: Started—Scheduled to start beginning of Year 2**
A sample of the DNA extracted from the North American African samples is being used by the laboratory of
Dr. Rick Kittles to survey a set of 100 ancestry informative markers. These studies will allow for accurate
estimates of European ancestries in the AA subjects, and allow use of individual ancestry estimates as
additional covariates in overall experimental analyses. We have sent an initial set of samples to Dr. Kittles to
begin this aim of the project, data from the samples is not yet available.

**Task 8: Aim I, Independent validation of gene expression differences using quantitative real-time
PCR. Status: Beginning—continues in Year 2**
Quantitative real-time PCR of a subset of statistically significant genes is being used as an independent
validation of gene expression differences. Additionally a set of genes will be investigated to validate the
combined data from the gene expression arrays and cGH arrays. As data analysis for both gene expression
and array CGH is ongoing, a final list of genes to be evaluated by real-time PCR is not yet available. We
have selected a subset of genes to be tested, such as the Estrogen Receptor gene, to investigate congruence
with the gene expression data and the ER negative status of the samples. The total number of genes analyzed

9

will a minimum be 10 over expressed genes and 10 under expressed genes, but the actual percentage of differentially expressed genes is to be determined after the total number of differentially expressed genes is know.

5) KEY RESEARCH ACCOMPLISHMENTS

- **Task 1:** Obtain UM IRB and USAMRMC HRPO Approvals. Completed.

- **Task 2:** Transport of Kijabe samples to the University of Miami. Completed

- **Task 3:** Determination of HER2 (and ER/PR) status in the Kijabe clinical cohort using fluorescence in situ hybridization. Underway.

- **Task 4**. Extraction and preparation of DNA and RNA from FFPE tumor samples from North American African, African African, and Caucasian cohorts. Underway

- **Task 5:** Aim I, Analyze and compare genome-wide transcript expression in BC samples of AA ancestry vs. native African (Kijabe) samples Underway

- **Task 6**: Aim II, Investigate possible chromosomal alterations associated with gene expression differences using array cGH. Underway

- **Task 7**. Aim III, Analyze ancestry of each sample using a panel of ancestry-informative DNA markers (AIMs**).** Started—scheduled for Year 2

- **Task 8:** Aim I, Independent validation of gene expression differences using quantitative real-time PCR—Beginning—continues in Year 2

6) REPORTABLE OUTCOMES

- **L**. **Baumbach**, J. Yan, M.E. Ahearn, C. Gomez, M. Jorda, T.A. Halsey, A. Mejias, K. Ellison, K. Mulligan, S. Gluck, **M. Pegram** (2009) Gene Expression Profiling of Formalin-fixed, Paraffin-embedded (FFPE) Tissues from Triple-negative (TN) Breast Cancer (BC) Patients Proceedings of the San Antonio Breast Cancer Symposium.

- **L**. **Baumbach**, J. Yan, M.E. Ahearn, C. Gomez, M. Jorda, T.A. Halsey, A. Mejias, K. Ellison, K. Mulligan, S. Gluck, **M. Pegram** (2009) Defining multi-ethnic genome-wide transcriptional signatures in normal and cancerous breast tissue using paraffin embedded samples. Proceedings of the American Association for Cancer Research, Special Symposium on Breast Cancer, San Diego, CA

- **L**. **Baumbach**, J. Yan, M.E. Ahearn, C. Gomez, M. Jorda, T.A. Halsey, A. Mejias, K. Ellison, K. Mulligan, S. Gluck, **M. Pegram** (2010) Defining multi-ethnic genome-wide transcriptional

signatures in normal and cancerous breast tissue using paraffin embedded samples. Nature Biotechnology Winter Symposium.

- **L. Baumbach**, J. Yan, M.E. Ahearn, C. Gomez, M. Jorda, T.A. Halsey, A. Mejias, K. Ellison, K. Mulligan, S. Gluck, **M. Pegram** (2010) Continued Identification of Ethnic Specific Differences in Breast Tissue using Archived FFPE Specimens. Zubrod Memorial Lecture and Cancer Research Poster Session.

- Baumbach, et al., Gene Expression Profiling of Formalin-fixed, Pariffin-embedded (FFPE) Tissues from Triple-negative Breast Cancer Patients (2010, *manuscript in preparation*).

7) CONCLUSION

We have demonstrated the utility and reliability of using archived FFPE tissues (including those obtained from native Africa) to complete the investigations proposed in this award – namely gene expression profiling and CGH array analysis. Prior to these investigations, there has not been a published study that simultaneously evaluates genome-wide gene expression differences between tumor and self-matched normal breast tissue in a series of African/AA and Cauc patients, and correlates these results to potential chromosome/DNA alterations in those same tumor specimens. This study will allow for the first direct comparison of gene expression/genomic copy number data in triple negative tumor specimens across Americans of African descent and Kenyan East Africans. These data sets will be posted to publically-accessible online microarray databases for immediate availability to the research community. Importantly, we have engaged an advocate who has participated in group meeting and will continue to help guide us in dissemination of our findings to the African American community. We will correlate all experimental data with a spectrum of clinical data available on study subjects, and determine possible correlations between genomic signatures, genomic changes, clinical tumor characteristics and outcomes/ response measures among and across ethnic groups. We are well on our way to completing the proposed tasks in the proposed timeframe.

8) REFERENCES

1. American Cancer Society (2007) Cancer Facts and Figures for African-Americans.
2. Chlebowski RT et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. *JNCI* 97:6, 439-48.
3. Albain KS et al (2003) Outcomes of African Americans in SWOG BC therapy trials.*Br Can Res Treat* 77:A21.
4 Shen Y et al (2007) Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M. D. Anderson Cancer Center? *Breast Cancer Res Treat* 102:347–356.
5. Ijaduola TG, Smith EB. (1998) Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. *J Natl Med Assoc.* 90(9):547-51.
6. Adebamowo CA, Ogundiran TO, Adenipekun AA et. al. (2003). Obesity and height in urban Nigerian women with breast cancer. *Ann Epidemiol.* Jul;13(6):455-61.
7. Adebamowo CA, Ogundiran TO, Adenipekun AA, et. al. (2003). Waist-hip ratio and breast cancer risk in urbanized Nigerian women. *Breast Cancer Res.* 5(2):R18-24.
8. Fackenthal JD, Sveen L, Gao Q, et al. (2005). Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients. *J Med Genet.* 42(3):276-81.

9. Huo D, Kim HJ, Adebamowo CA,. et. al. (2007) Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. *Breast Cancer Res Treat.* 2007 Oct 2. [Epub ahead of print]
10. Huo D, Adebamowo CA, Ogundiran TO,.et. al. (2008) Parity and breastfeeding are protective against breast cancer in Nigerian women. *Br J Cancer.* 98(5):992-6.
11. Bird PA, Hill AG, Houssami N. (2008) Poor hormone receptor expression in East African Breast Cancer: Evidence of a Biologically Different Disease? *Annals of Surgical Oncology* 2008 (in press).
12. Baumbach, et al., Gene Expression Profiling of Formalin-fixed, Pariffin-embedded (FFPE) Tissues from Triple-negative Breast Cancer Patients (2010, manuscript in preparation).

9) APPENDICES – sample poster presentation; American Association for Cancer Research, Special Symposium on Breast Cancer, San Diego, CA 2009; *Manuscript in preparation available on request.*

Defining multi-ethnic genome-wide transcriptional signatures in normal and cancerous breast tissue using paraffin embedded samples

Lisa L. Baumbach[1], Mary Ellen Ahearn[1], Carmen Gomez[1], Aldo Mejias[1], Merce Jorda[1], Tom Halsey[2], Jim Yan[2], Kevin Ellison[2], Karl Mulligan[2], Stefan Gluck[1] and Mark Pegram[1]

1) Miller School of Medicine, University of Miami, Miami, FL; 2) Almac Diagnostics, Durham, North Carolina

Overall Study Design

The overall goal of the project is to investigate possible ethnic differences in gene expression in breast cancer when patient samples are matched for age, stage of disease and hormone receptor status. For each sample normal tissue from the same woman is used as a control to evaluated gene expression from the tumor tissue.

The final study will include 10 each African-American, Hispanic white and non-Hispanic white (Caucasian) women.

The study was originally designed to use fresh tissue samples but with the advent of the Breast Cancer DSA™ Research Tool has changed to using Formalin Fixed Paraffin Embedded (FFPE) samples.

Patient Study Criteria:
 Age 60 years or less
 No exposure to chemotherapy
 Triple Negative hormone receptor status

Almac Diagnostics Cancer DSA™ research tools

Standard microarrays provide large quantities of information, but are broadly representative of the human genome rather than a particular disease state.

The Breast Cancer DSA™ was developed by a process of high throughput sequencing, gene expression profiling and bioinformatics analysis, to fully characterize the transcriptome of disease and normal tissue. Therefore, it includes significant additional relevant data not available from other microarrays.

The Breast Cancer DSA™ research tool contains approximately 60,000 transcripts and is manufactured on Affymetrix GeneChip® technology.

Sequence analysis comparing the Breast Cancer DSA™ research tool with two leading commercially available generic microarrays clearly highlights the extent of its unique content as demonstrated in the figure below.

Almac Diagnostics Breast Cancer DSA™ Research Tool Compared with Two Commercially Available Generic Microarrays

37% Unique — 63% Similar
Generic Microarray A

57% Unique — 43% Similar
Generic Microarray B

Technical Specifications of the Breast Cancer DSA™ Research Tool	
Number of transcripts	~60,000
Feature Size	11 micron
Probe Length	25-mer
Probe Pairs/Probeset	11
Normalization Ctrl Probesets	100
Hybridization/Housekeeping Ctrl Probesets	62

Comparison of Breast Cancer DSA™ to the RefSeq database showed that 51% of the Breast Cancer DSA™ content is not present in the RefSeq database and 8% of the content represents antisense sequences to annotated transcripts.

Breast Cancer DSA™ and detection of differentially expressed transcripts

Technical assessment: Use with FFPE
The number of transcripts that were called present and were above the background in both RNAlater and FFPE samples was determined as shown in the table below.

	Transcripts detected in RNAlater	Transcripts detected in FFPE	Number of FFPE detected transcripts also detected in RNAlater
Breast Cancer DSA™ Research Tool	28,716	19,930	19,032
Affymetrix HG-U133 Plus 2	25,473	11,709	11,441

The high degree of data retention clearly demonstrates the power of the Breast Cancer DSA™ research tool when used in FFPE studies.

Use of the Breast Cancer DSA™ research tool in detection of differentially expressed transcripts
In most experimental studies, the end point of the analysis is the detection of differentially expressed transcripts. Analysis was carried out to determine the number of differentially expressed transcripts between normal and tumour tissue in our example study, defined as transcripts called present and above background with a fold change greater than 2 standard deviations of the mean with p-value <0.05. As can clearly be seen a large number of differentially expressed transcripts are detected in this experiment using both RNAlater and FFPE extracted samples. It is important to note that this experimental design is based on matched tumour and normal tissue from a single patient.

Current ER-/PR-/Her2- Breast Cancer Patients— FFPE Samples

Ethnicity	Normal	Tumor
African-American women (AA)	10 samples	10 samples
Caucasian women (Cau)	8 samples	8 samples
Hispanic women (His)	10 samples	10 samples

Methods for RNA Extraction and Hybridization

Patient samples were obtained from the University of Miami Medical School Pathology Department, under IRB approval, as anonymous samples. All samples were from women less than 60 years of age and were known to be ER+/PR+/Her2-.

For each patient, pathologists cut new sections from paraffin-embedded sample blocks for normal tissue and for tumor tissue. Samples were sent to Almac Diagnostics for processing and hybridization to the Breast Cancer DSA™ Research Tool.

The following steps were performed by Almac Diagnostics:

1. Isolation of RNA from each sample
2. RNA Amplification using the NuGEN FFPE System
3. Generation of First Strand cDNA from 10-80 ng of total RNA
4. Generation of a DNA/RNA Heteroduplex Double Strand cDNA and amplification
5. cDNA Fragmentation and Labelling using a NuGEN System
6. Affymetrix Hybridisation Washing, Staining and Scanning Protocol applied to the Breast Cancer DSA™ Research Tool.

Detection of Expressed Genes in Normal and Cancer FFPE Breast Samples by BC DSA

Number of Transcripts Detected by Ethnic Group

	AA	CAU	HIS
Detected in Tumor	3330	4164	4727
Detected in Normal	1859	1255	841
Detected in Both	16061	14504	10182

Numbers of Expressed Genes Detected in Breast Cancer Tumor FFPE Samples

AA Tumor 3330 | 16061 | AA Normal 1859

● 50160_2_AA_tumor_Detected (19,391)
● 50160_2_AA_normal_detected (17,920)

21250 transcripts are expressed on the Breast Cancer DSA with intensity significantly above background.
Data from self-matched tumor and normal breast tissue was compared for the three ethnic groups
There are some genes (several hundreds to over a thousand) are detected in one or two ethnic groups.

Summary of Data Analysis Strategy

Statistical analysis to Significant transcripts
→ 2-way ANOVA (Disease and race)
→ Paired t-test
→ Presence or Absence
→ Highly significant genes
→ Clustering Analysis to identify patterns
→ Pathway Analysis

Cluster Analysis of Individual Tumor and Matched Normal Samples from Patients of Three Ethnicities

➤2-dimentional K-Mean Clustering of 28 patient samples, 10 African-American, 10 Hispanic and 8 Caucasian.

➤Two main dendrogram groupings are seen: on the left (blue samples) self-matched normal samples, on the right (yellow samples) the tumor samples. Note the similarity of heatmaps of individual samples within a dendrogram group.

Native African Triple Negative Breast Cancer Comparison with Normal Breast Tissue Samples

AA "Tumor Normal"   Native African TN BC

➤A limited test set of triple negative breast cancer samples were obtained from collaborators at the Kijabe Kenya Hospital.

➤Presented here are results from analysis of the first three native African samples. Initial comparison shows that high quality RNA can be extracted from the Kijabe samples.

➤All samples were anonymous FFPE samples, hormone receptor status was verified by UM Pathology.

➤An analysis of additional Kijabe TN BC samples with African American "tumor normal" and "normal normal" tissue samples is underway.

Cluster Analysis of Patient Samples from Three Ethnicities with Normal Breast Tissue Samples

➤ Three main dendrogram groupings of transcripts are seen: on the left are the clustered tumor samples, second (the middle group) are the self matched normal cells adjacent to the patient tumor cells (termed "tumor normal"), lastly on the right is a cluster of "normal normal" samples obtained from non-cancer patients undergoing reduction mammoplasty. (up-regulation of genes red and down-regulation green).

➤"Normal Normal" samples included 4 African-American, 3 Hispanic and 3 Caucasian samples.

➤The 2-dimentional clustering of intensity data included 1442 probe sets selected based on their intensity (intensity>Background+3stdev, p-value <=0.01), 2-way ANOVA p*<0.01 (With MTC by Benjamini-Hochberg FDR).

➤Although "tumor normal" cells appear to be normal by pathology, it is apparent that gene expression alterations have occurred when compared to "normal normal" tissue from non-cancer patients.

Summary and Conclusions

➤ Gene expression differences have been demonstrated to exist between BC "tumor normal" and "normal normal" tissue; suggesting that the tumor microenvironment has a strong influence upon surrounding "normal" cells.

Current Status of Project:
1. We are selecting approximately 10 differentially expressed genes for validation by qRT-PCR, and we are extracting DNA from a subset of these specimens for hybridization to high-density SNP arrays, to assay possible DNA copy number variations (CNV's) and/or LOH in tumor samples.

2. We are currently adding triple negative breast cancer samples from native Africans (Kijabe, Kenya) to the study. Initial studies show that high quality RNA can be obtained from the samples, and show gene expression difference from African-American samples.

➤ The ability to obtain high quality RNA expression data from FFPE samples, illustrated here, offers new possibilities for genetic studies. Completion of this study should result in significant findings regarding genome-wide alterations associated with BC in several ethnic/racial groups, and increase understanding of the biological basis of ethnic-specific disparities in BC occurrence, mortality and therapeutic response.